Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02229149 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer
A Phase 2 study, sponsored by US Oncology Research.
- Terminated
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT02229149 is a Phase 2 study that was terminated before completion, run by US Oncology Research. The registered enrollment target is 33 participants.
The verdict
NCT02229149, a Phase 2 study, was terminated before completion, sponsored by US Oncology Research.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
This randomized phase 2 study will seek to determine the effectiveness of chemotherapy (physician's choice of vinorelbine, taxane \[paclitaxel, docetaxel or nab paclitaxel\] or capecitabine) plus trastuzumab vs chemotherapy (physician's choice) plus trastuzumab plus pertuzumab in women with HER2-overexpressing metastatic breast (MBC) that has been previously treated with ado-trastuzumab emtansine (T-DM1) in the metastatic setting.
Interventions
- DRUG Trastuzumab
- DRUG Pertuzumab
- DRUG Vinorelbine, Paclitaxel, Nab-Paclitaxel , Docetaxel, Capecitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2014-12 |
| Est. Completion | 2022-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02229149
The ClinicalTrials.gov registry entry for NCT02229149 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is US Oncology Research, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Trastuzumab is the first listed.
NCT02229149 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02229149 about?
NCT02229149 is a clinical study titled "Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer". This randomized phase 2 study will seek to determine the effectiveness of chemotherapy (physician's choice of vinorelbine, taxane \[paclitaxel, docetaxel or nab paclitaxel\] or capecitabine) plus trastuzumab vs chemotherapy (physician's choice) plus trastuzumab plus pertuzumab in women with HER2-ove...
What is the current status of trial NCT02229149?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2014-12. Estimated completion is 2022-01.
What interventions are being tested in trial NCT02229149?
The interventions under investigation include: Trastuzumab (DRUG), Pertuzumab (DRUG), Vinorelbine, Paclitaxel, Nab-Paclitaxel , Docetaxel, Capecitabine (DRUG).
Who is sponsoring clinical trial NCT02229149?
This trial is sponsored by US Oncology Research, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.